PhorMed is a biopharmaceutical company focused on developing and commercializing its lead technology, RP-323, which is a targeted cell repair therapy and immunotherapy. This innovative treatment aims to promote the body's natural healing processes by reducing inflammation and addressing various diseases, including acute myeloid leukemia (AML), Hodgkin's lymphoma, Parkinson's disease, and acute respiratory distress syndrome (ARDS). RP-323 operates by activating protein kinase C, which plays a crucial role in cellular differentiation, proliferation, and apoptosis. The therapy has shown promising results in clinical trials, demonstrating a favorable safety profile and the ability to induce significant biological effects in treating hematological malignancies and neurological disorders.

The proprietary nature of RP-323 allows it to target multiple cell lines, enhancing its potential applications across a range of inflammatory and malignant conditions. PhorMed's ongoing research includes Phase II studies for AML and Hodgkin's lymphoma, as well as preclinical studies for Parkinson's disease and ARDS. The company is committed to advancing its pipeline through collaborations with clinical sites and leveraging its intellectual property portfolio to drive innovation in drug research and development. With a focus on achieving effective treatments with tolerable side effects, PhorMed aims to make significant contributions to the healthcare sector and improve patient outcomes.

United States

PhorMed is a biopharmaceutical company leading the charge in the field of genomic medicine. We are working to utilize gene therapy to treat diseases, allowing the body to heal, and give new hope to patients suffering from diseases like AML, Hodgkin’s Lymphoma, Parkinson’s disease, and viruses.

Cancer

Cardiovascular Diseases

Central Nervous System (CNS)

Immune System Diseases

Infectious Diseases

Lung Diseases

Lymphatic Diseases

Nervous System Diseases

PhorMed

Acute myeloid leukemia

Hodgkin Lymphoma

RP-323

Biologics

Gene Therapy

Acute respiratory distress syndrome

COVID-19

Stroke

California - South

California

Small Molecule Pharmaceuticals

Therapeutic

PhorMed

Company Details